Beyond the White Pill: Advocating for Racial Diversity in IBD Trials

Although inflammatory bowel disease [IBD] affects an increasingly diverse patient population, most patients in IBD clinical trials are White. Acknowledging current barriers and taking meaningful action is required at multiple levels to improve racial diversity across clinical trials in IBD. Ultimately, improving racial diversity in trials can in turn improve the care received by the diverse patients seen in clinical practice.

Automated summary

Improving racial diversity in IBD clinical trials requires action at multiple levels to increase opportunities for patients of all races to participate in trials, ultimately leading to improved care for diverse patients in clinical practice.